Literature DB >> 21686530

Pleural effusion: what lies underneath?

L Vaz Rodrigues1, J Raposo, C Mendonça, A Figueiredo, F Barata, M Meruje, J Pires.   

Abstract

Malignant mesothelioma is a tumour of serous surfaces mainly arising at the pleura or the peritoneum. The diagnosis encompasses multiple problems as there is no pathognomonic hallmark for the disease, there are multiple histological types and the differentiation from other tumours, such as adenocarcinoma or metastatic pleural disease, can represent quite a challenge. Usually a diagnosis of malignant mesothelioma carries a dismal prognosis with scarce therapeutical options.The present report concerns a patient with a diagnosis of malignant pleural mesothelioma with endobronchial extension. Biopsy specimens were obtained through fibreoptic bronchoscopy and blind needle pleural biopsy. The final diagnosis was only possible after careful histological evaluation with a combination of immunohistochemical markers.

Entities:  

Year:  2009        PMID: 21686530      PMCID: PMC3028575          DOI: 10.1136/bcr.09.2008.0973

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

Authors:  William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

Review 2.  Advances in malignant mesothelioma.

Authors:  Bruce W S Robinson; Richard A Lake
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

Review 3.  What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.

Authors:  Nelson G Ordóñez
Journal:  Hum Pathol       Date:  2006-10-23       Impact factor: 3.466

4.  Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.

Authors:  Andy Hughes; Paula Calvert; Ashraf Azzabi; Ruth Plummer; Rob Johnson; Jim Rusthoven; Melanie Griffin; Kevin Fishwick; Alan V Boddy; Mark Verrill; Hilary Calvert
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

5.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

6.  The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.

Authors:  Nelson G Ordóñez
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

7.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

Authors:  Giovanni L Ceresoli; Paolo A Zucali; Adolfo G Favaretto; Francesco Grossi; Paolo Bidoli; Guido Del Conte; Anna Ceribelli; Alessandra Bearz; Emanuela Morenghi; Raffaele Cavina; Maurizio Marangolo; Hector J Soto Parra; Armando Santoro
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

8.  Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.

Authors:  Markku Miettinen; Maarit Sarlomo-Rikala
Journal:  Am J Surg Pathol       Date:  2003-02       Impact factor: 6.394

9.  Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Authors:  David M Jackman; Hedy L Kindler; Beow Y Yeap; Panos Fidias; Ravi Salgia; Joan Lucca; Linda K Morse; Patricia A Ostler; Bruce E Johnson; Pasi A Jänne
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

10.  Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.

Authors:  Hadi Yaziji; Hector Battifora; Todd S Barry; Harry C Hwang; Carlos E Bacchi; Martin W McIntosh; Steven J Kussick; Allen M Gown
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.